peoplePerson
Owen N. Witte
Discovered the BCR-ABL kinase activity that imatinib blocks and now hunts for new prostate cancer targets.
Molecular biologist who identified the tyrosine kinase activity of the BCR-ABL oncoprotein, the basis of imatinib. His lab now defines prostate cancer lineage plasticity and targets such as PSCA and STEAP1 for immunotherapy.
Role
University Professor; Founding Director Emeritus, Broad Stem Cell Research Center, UCLA
Institution
Specialisms
Prostate cancer biologyKinase signallingImmunotherapy targets
Profiles